China Pharma Holdings (CPHI) Interest Expenses (2010 - 2026)

China Pharma Holdings has reported Interest Expenses for 17 years, with the latest figure at $9085.0 in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 33.86% year-over-year to $9085.0; the trailing twelve-month figure through Mar 2026 stood at $29541.0 (up 8.27% YoY), and the FY2025 full-year result was $27272.0, changed 0.3% from the prior year.
• Interest Expenses for Q1 2026 stood at $9085.0, up from $6879.0 in the prior quarter.
• The five-year high for Interest Expenses was $137663.0 in Q2 2023, with the low at -$244593.0 in Q4 2022.
• Historically, Interest Expenses has averaged $15040.2 across 5 years, with a median of $6856.0 in 2024.
• The largest YoY upside for Interest Expenses was 3574.75% in 2022 against a maximum downside of 624.26% in 2022.
• China Pharma Holdings' Interest Expenses stood at -$244593.0 in 2022, then jumped by 103.98% to $9745.0 in 2023, then slumped by 30.2% to $6802.0 in 2024, then climbed by 1.13% to $6879.0 in 2025, then jumped by 32.07% to $9085.0 in 2026.
• The last three Interest Expenses figures came in at $9085.0 (Q1 2026), $6879.0 (Q4 2025), and $6798.0 (Q3 2025), per Business Quant data.